Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.
Immuron Limited (NASDAQ: IMRN, ASX: IMC) is an Australian biopharmaceutical company focused on orally delivered targeted polyclonal antibodies for infectious and inflammatory mediated diseases. The Immuron news feed on Stock Titan aggregates company announcements, market updates and regulatory disclosures so readers can follow developments around its commercial products and clinical pipeline.
News about Immuron frequently highlights Travelan®, an over‑the‑counter immune supplement and dietary supplement based on hyper‑immune bovine antibodies that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Company updates have reported record Travelan sales in Australia and North America, marketing initiatives in retail and online channels, and clinical trial activity involving IMM‑124E, the active ingredient in Travelan, in collaboration with the Uniformed Services University.
Investors and followers can also expect coverage of pipeline milestones such as FDA interactions and clinical plans for IMM‑529, a candidate for Clostridioides difficile infection, and IMM‑986, a pre‑clinical program targeting vancomycin‑resistant enterococci. Immuron’s announcements describe pre‑clinical results, Investigational New Drug submissions and approvals, and collaborations with institutions including Naval Medical Research Command, Walter Reed Army Institute of Research and Monash University.
In addition, the news stream includes letters to shareholders, sales updates, distribution agreements such as the ProIBS® IBS product in Australia and New Zealand, and corporate communications about investor engagement initiatives. Bookmark this page to access a consolidated view of Immuron’s operational, clinical, commercial and corporate news as it is released through official channels.
Summary not available.
Summary not available.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has released its Q3 FY23 Investor Presentation, highlighting significant sales growth. For the two weeks ending April 14, 2023, worldwide sales reached A$320,000, representing 37% of the entire Q3 FY23 total of A$875,000. Year-to-date sales for FY23 until April 14 amounted to A$1,779,000, marking a remarkable 233% increase compared to A$534,000 for the same period in FY22. The company is focusing on its oral immunotherapeutic products for gut-mediated diseases. Investors are invited to participate in a webinar hosted by CEO Steven Lydeamore for further insights.
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a biopharmaceutical company based in Australia, announced a business update for the quarter ending 31 March 2023. The update will be presented during a live webcast hosted by CEO Steven Lydeamore on 19 April 2023 at 11:00 AM (AEST). The company is known for its orally administered immunotherapeutic products, particularly Travelan®, which is used to prevent travelers' diarrhea. Travelan® is available in Australia and Canada as a therapeutic product and a licensed natural health product, respectively, and in the U.S. as a dietary supplement. The company is focused on developing targeted polyclonal antibodies for treating inflammatory and infectious diseases.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported robust sales results for Q3 FY23, highlighting a significant turnaround in demand for its gastrointestinal products, Travelan® and Protectyn®.
Sales soared to A$1.46 million year-to-date, reflecting a 239% increase from A$430k in the same period last year. In Australia, Q3 FY23 sales reached A$577k, representing 201% of first-half sales. North American sales mirrored this trend, with Q3 reaching A$298k, equating to 100% of first-half sales.
This growth is attributed to a rebound in overseas travel and increasing sales through clinics and distributors, emphasizing the company’s strategy to restock and build inventory. Immuron remains committed to expanding its product portfolio and driving sales growth.
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a biopharmaceutical company based in Australia, invites investors to a live webcast hosted by CEO Steven Lydeamore on February 28, 2023, at 11:00 AM AEDT. Immuron specializes in developing oral immunotherapeutic products for gut-mediated diseases, with its flagship product, Travelan®, approved in Australia and Canada to reduce the risk of Travelers' Diarrhea. In the U.S., it is marketed as a dietary supplement. This event aims to provide insights into the company's product offerings and future plans.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has submitted a response letter to the US FDA regarding a clinical hold on their oral therapeutic targeting Campylobacter and ETEC. This was in response to FDA feedback from its review of the Investigational New Drug (IND) application submitted on July 26, 2022. A virtual meeting held on December 2, 2022, with the FDA, Naval Medical Research Center (NMRC), and Johns Hopkins University discussed the hold and how to address safety concerns. The FDA is expected to provide feedback on the submitted information package within 30 days.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has enrolled its first participants in the USU Travelan Clinical Trial Field Study, successfully randomizing 157 participants out of a target of 1302 volunteers. This clinical trial, conducted by USU's Infectious Diseases Clinical Research Program in partnership with the UK Ministry of Defense and the New York City Travel Clinic, aims to evaluate the efficacy of Travelan against Travelers’ Diarrhea. The study, designed to assess passive immunotherapy, is set to complete enrollment in roughly 18 months. Travelers' diarrhea poses significant health risks, especially for military personnel, highlighting the need for effective preventative strategies.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announces the grant of a European Patent for the treatment and prevention of Clostridioides difficile infections. This patent, European Patent No. 2986316, enhances the company's intellectual property portfolio, complementing existing patents in Australia, New Zealand, and the United States. Clostridioides difficile infection (CDI) poses significant healthcare challenges, affecting up to 1.2% of hospitalized patients in the U.S., with annual costs approximating USD 4.8 billion. The growing incidence of CDI highlights the urgency for effective treatments as the population ages, particularly in Europe.
Immuron has received FDA approval for its Travelan Investigational New Drug (IND) application aimed at preventing infectious diarrhea caused by enterotoxigenic E. coli (ETEC). The IND is now active, and a clinical trial will commence in the US with plans to recruit 60 healthy volunteers. The trial will evaluate the efficacy of a single 1200 mg dose of Travelan in a controlled environment. Results are expected by year-end 2023. This treatment is significant for travelers and military personnel, given the rising antibiotic resistance affecting traditional treatments.